ETHNOBOTANICAL BASED ANTI-RSV THERAPEUTICS

呼吸道合胞病毒（RSV）可引起婴儿、幼儿和成人的下呼吸道感染，如细支气管炎和肺炎。在缺乏有效的疫苗和争议较少的化合物来预防或改善RSV感染的情况下，RSV仍然是一种严重的健康威胁，必须持续努力寻找具有增强功效的新药物。我们已经鉴定了一种民族植物学（EB）制剂（ZX-2187 P），其显示出显著的抗RSV活性。本申请的总体范围是研究这种EB制剂作为控制RSV感染的治疗剂的潜力。具体目的包括：使用体外试验系统在多个细胞系中评价ZX-2187 P对多种RSV毒株的抗RSV活性，进行ZX-2187 P的体内抗RSV评价，进行实验以阐明ZX-2187 P的作用机制，并进行ZX-2187 P的提取、分级分离和纯化以鉴别纯化合物。拟议的商业应用：RSV是婴儿和幼儿的主要病毒病原体，是成人疾病的重要原因，并导致老年人的大量发病率和死亡率。没有疫苗可用，并且批准使用的利巴韦林和免疫球蛋白的组合昂贵且难以施用。因此，可以控制RSV感染的任何新试剂都具有巨大的经济影响。

Respiratory syncytial virus (RSV) causes lower respiratory tract infections such as bronchiolitis and pneumonia in infants, young children and adults. In the absence of an effective vaccine and less controversial compounds to prevent or ameliorate RSV infections, RSV remains a serious health threat and a sustained effort must be mounted to find new agents with enhanced efficacy. We have identified an Ethnobotanical (EB) preparation (ZX-2187P) that shows significant anti-RSV activity. The overall scope of this application is to investigate the potential of this EB preparation as a therapeutic for controlling RSV infections. The specific aims include, evaluation of anti-RSV activity of ZX-2187P against multiple RSV strains in multiple cell lines using in vitro assay systems, performing in vivo anti-RSV evaluation of ZX-2187P, conducting experiments to elucidate the mechanism(s) of action of ZX-2187P and performing extraction, fractionation and purification of ZX-2187P to identify pure compound(s). PROPOSED COMMERCIAL APPLICATIONS: RSV is a major virus pathogen of infants and young children, an important cause of disease in adults and is responsible for a significant amount of morbidity and mortality in the elderly. No vaccines are available and the combination of ribavirin and immunoglobulin approved for use is expensive and difficult to administer. Thus, any new agent(s), which can control RSV infection, has a huge economical impact.